LifeSci Capital Initiates Coverage On Immunome with Outperform Rating, Announces Price Target of $20

Benzinga · 03/11 12:38
LifeSci Capital initiates coverage on Immunome (NASDAQ:IMNM) with a Outperform rating and announces Price Target of $20.